Gambichler T, Girke S, Abu Rached N, Susok L, Becker J, Schulze H
Cancers (Basel). 2025; 17(5).
PMID: 40075669
PMC: 11899218.
DOI: 10.3390/cancers17050822.
Zhang M, Yang Y, Liu J, Guo L, Guo Q, Liu W
Exp Biol Med (Maywood). 2025; 250:10235.
PMID: 40008144
PMC: 11851207.
DOI: 10.3389/ebm.2025.10235.
Kummar S, Abdul Razak A, Laurie S, Glatt D, Kell S, Diep A
Cancer Res Commun. 2024; 5(1):94-105.
PMID: 39651931
PMC: 11734590.
DOI: 10.1158/2767-9764.CRC-24-0568.
Sun W, Hu S, Wang X
Cancer Commun (Lond). 2024; 44(9):1071-1097.
PMID: 39073258
PMC: 11492363.
DOI: 10.1002/cac2.12587.
Gorczynski R
Genes (Basel). 2024; 15(3).
PMID: 38540350
PMC: 10970502.
DOI: 10.3390/genes15030292.
CD200/CD200R: Bidirectional Role in Cancer Progression and Immunotherapy.
Nip C, Wang L, Liu C
Biomedicines. 2023; 11(12).
PMID: 38137547
PMC: 10741515.
DOI: 10.3390/biomedicines11123326.
Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200.
Moon S, Han M, Ryu G, Shin S, Lee J, Lee C
Int J Mol Sci. 2023; 24(20).
PMID: 37894750
PMC: 10606340.
DOI: 10.3390/ijms242015072.
The Use of CD200 in the Differential Diagnosis of B-Cell Lymphoproliferative Disorders.
Al-Zubaidi H, Hughes S
Br J Biomed Sci. 2023; 80:11573.
PMID: 37822353
PMC: 10563807.
DOI: 10.3389/bjbs.2023.11573.
Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome.
Guo X, Yu S, Ren X, Li L
Heliyon. 2023; 9(9):e19222.
PMID: 37810157
PMC: 10558320.
DOI: 10.1016/j.heliyon.2023.e19222.
Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy.
Tang Y, Liu W, Kadu S, Johnson O, Hasanali Z, Kelly A
Blood. 2023; 143(2):139-151.
PMID: 37616575
PMC: 10862366.
DOI: 10.1182/blood.2022018658.
Checkpoint Inhibitors in Acute Myeloid Leukemia.
Damiani D, Tiribelli M
Biomedicines. 2023; 11(6).
PMID: 37371818
PMC: 10295997.
DOI: 10.3390/biomedicines11061724.
Diagnostic Utility of CD200 Immunohistochemistry in Distinguishing EBV-Positive Large B-Cell Lymphoma From Classic Hodgkin Lymphoma.
Batuello C, Mason E
Am J Clin Pathol. 2023; 160(3):284-291.
PMID: 37227967
PMC: 10472740.
DOI: 10.1093/ajcp/aqad053.
Combination CD200R/PD-1 blockade in a humanised mouse model.
Fellermeyer M, Anzilotti C, Paluch C, Cornall R, Davis S, Gileadi U
Immunother Adv. 2023; 3(1):ltad006.
PMID: 37082107
PMC: 10112683.
DOI: 10.1093/immadv/ltad006.
Cancel cancer: The immunotherapeutic potential of CD200/CD200R blockade.
Choe D, Choi D
Front Oncol. 2023; 13:1088038.
PMID: 36756156
PMC: 9900175.
DOI: 10.3389/fonc.2023.1088038.
A potential area of use for immune checkpoint inhibitors: Targeting bone marrow microenvironment in acute myeloid leukemia.
Aru B, Pehlivanoglu C, Dal Z, Dereli-Caliskan N, Gurlu E, Yanikkaya-Demirel G
Front Immunol. 2023; 14:1108200.
PMID: 36742324
PMC: 9895857.
DOI: 10.3389/fimmu.2023.1108200.
The immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy.
Shao A, Owens D
Oncotarget. 2023; 14:96-103.
PMID: 36738455
PMC: 9899099.
DOI: 10.18632/oncotarget.28354.
Present and Future Role of Immune Targets in Acute Myeloid Leukemia.
Damiani D, Tiribelli M
Cancers (Basel). 2023; 15(1).
PMID: 36612249
PMC: 9818182.
DOI: 10.3390/cancers15010253.
High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4 T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens.
Iversen K, Nederby L, Lund T, Plesner T
Clin Hematol Int. 2022; 4(3):107-116.
PMID: 36131131
PMC: 9492812.
DOI: 10.1007/s44228-022-00013-7.
Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the immune checkpoint family in acute myeloid leukemia.
Xu Z, Zhang X, Jin Y, Wang S, Gu Y, Ma J
Mol Ther Oncolytics. 2022; 26:88-104.
PMID: 35795094
PMC: 9233190.
DOI: 10.1016/j.omto.2022.05.011.
The Role of CD200-CD200 Receptor in Human Blood and Lymphatic Endothelial Cells in the Regulation of Skin Tissue Inflammation.
Rutsche D, Michalak-Micka K, Zielinska D, Moll H, Moehrlen U, Biedermann T
Cells. 2022; 11(6).
PMID: 35326506
PMC: 8947338.
DOI: 10.3390/cells11061055.
